Difference between revisions of "Deferasirox (Exjade)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 25: | Line 25: | ||
[[Category:FDA approved in 2005]] | [[Category:FDA approved in 2005]] | ||
| + | [[Category:Health Canada approved in 2006]] | ||
Latest revision as of 17:52, 29 March 2023
General information
Class/mechanism: Iron chelating agent; selective for the ferric form of iron: iron(III), Fe3+.[1][2][3]
Route: PO (powder); the PO tablet form of this medication is Deferasirox (Jadenu)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Iron overload, secondary hemochromatosis
Patient drug information
- Brief patient counseling information can be found on Deferasirox (Exjade) package insert pages 21-22[1]
- Deferasirox (Exjade) patient drug information (UpToDate)[4]
Also known as
- Brand name: Exjade